LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
$2.18
arrow_downward
-9.54%(-0.23) 1D
$2.20
arrow_upward
+0.92% (+0.020)bedtimeAfter hours
Closed: Aug 20, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LXRX...
Open
$2.40
High
$2.40
Low
$2.17
Mkt. cap
970.00M
Avg. vol.
2.73M
Volume
4.74M
52-wk high
$2.68
52-wk low
$1.03
EPS
-$0.15
Beta
1.37
Shares outstanding
444.96M
No. of employees
81
Open
$2.40
High
$2.40
Low
$2.17
Mkt. cap
970.00M
Avg. vol.
2.73M
Volume
4.74M
52-wk high
$2.68
52-wk low
$1.03
EPS
-$0.15
Beta
1.37
Shares outstanding
444.96M
No. of employees
81
News stories
From web sources and news partners
Simply Wall Street
·
8 hours ago
The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift
Vinanet
·
1 day ago
Lexicon (LXRX) Levels: Slides 0.41% to $2.41 in the Current Update; Technical Setup
MarketBeat
·
2 days ago
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving Average - Here's Why
Vinanet
·
3 weeks ago
LXRX Earnings Overview 2026-07-30 - Net Profit Margin
Profile
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
About Lexicon Pharmaceuticals Inc
AI content may include mistakes. Learn more